Abstract |
In 60 patients with mitral valve prolapse syndrome a randomized controlled interindividual double-blind study of propranolol (p) was performed. Patients received p 80 mg (A), 160 mg (B) and placebo (C) orally for 4 weeks. Prior to and after treatment, heart rate (HR) and blood pressure (RR) as well as systolic time intervals ( STI) were measured and corrected for heart rate--electromechanical systole (QS2I), left ventricular ejection time (LVETI), and preejection period (PEPI). The ratio PEP/LVET was calculated. Plasma levels were measured by an optimized fluorimetric method. 1. STI lay in the upper part of the normal range, indicating that some patients had a hyperkinetic cardiac function. 2. P had no influence on QS2I and LVETI in A and B. PEPI was prolonged (A: +13.2 ms, B: +14.2 ms) and PEP/LVET was increased (A: +0.040, B: +0.050). 3. As indicated by the changes in HR, RR, PEPI, and PEP/LVET p showed in B compared to A only minor additional effects. 4. Plasma levels of p were in B three times higher than in A (A: 89.2 +/- 10.0 nmol/l B: 246.7 +/- 30.5 nmol/l). With a dose of 80 mg propranolol a point close to the plateau of maximum efficacy was reached, where a higher dose resulted only in small additional negative inotropic effects.
|
Authors | R Erbel, G Wagner, P Schweizer, M Schäfer, W Merx, E Mutschler, S Effert |
Journal | International journal of clinical pharmacology and biopharmacy
(Int J Clin Pharmacol Biopharm)
Vol. 17
Issue 11
Pg. 457-63
(Nov 1979)
ISSN: 0340-0026 [Print] Germany |
PMID | 389839
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
|
Topics |
- Clinical Trials as Topic
- Double-Blind Method
- Female
- Hemodynamics
(drug effects)
- Humans
- Male
- Mitral Valve Prolapse
(drug therapy, physiopathology)
- Placebos
- Propranolol
(blood, therapeutic use)
|